返回

Knight wins Colombian approval for TAVALISSE in chronic ITP

正在验证中
  • Knight Therapeutics received INVIMA approval for TAVALISSE in adult chronic ITP patients.
  • August 31, 2026 marked the approval date cited in the prescribing information.
  • Knight launched TAVALISSE in Mexico in May 2026 and plans Colombian sales in 2027.
本网站上的信息是使用AI生成的，我们无法保证其准确性。 请仅作为参考信息使用。